Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
Intravesical Bacilli Calmette-Guérin (BCG) immunotherapy is a commonly used treatment for superficial bladder cancer. Although the treatment is well tolerated in 95% of cases, life-threatening side effects including BCG sepsis can occur. This report describes the case of an 82-year-old man with a ba...
Saved in:
| Main Authors: | S. Lukacs, B. Tschobotko, N. A. Szabo, Andrew Symes |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Case Reports in Urology |
| Online Access: | http://dx.doi.org/10.1155/2013/821526 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
by: Uyen To, et al.
Published: (2014-01-01) -
Intravesical Therapy of Superficial Urothelial Bladder Cancer with BCG and Epirubicin 50 Mg - Comparative Analysis
by: Boyan Atanasov, et al.
Published: (2022-06-01) -
Bladder Preservation With Transurethral Tumor Resection and Intravesical BCG Instillation in Superficial Muscle-Invasive Bladder Cancer: A 10-Year Follow-up
by: Dong Gyun Kim, et al.
Published: (2023-03-01) -
Psoriasis exacerbation following intravesical BCG immunotherapy for bladder carcinoma: A case report
by: Yusuf Can Edek, et al.
Published: (2025-07-01) -
Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol
by: Roberta Monardo, et al.
Published: (2025-01-01)